Manufacturing Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb PharmaTimesAragen scales Daretabart to commercial-ready production following rapid 9month tech transferRead full story pharminent June 2, 2026 (Last updated: June 4, 2026) PharmaTimes Aragen scales Daretabart to commercial-ready production following rapid 9month tech transfer Read full story Post navigation Previous: The 340B Contract Pharmacy Market in 2026: A Maturing Industry Dominated by Big Chains and PBMsNext: BMS secures FDA acceptance for Camzyos sNDA Related Stories Manufacturing Samsung Biologics inks $262M manufacturing deal with European pharma company pharminent September 11, 2026 Manufacturing Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision pharminent September 9, 2026 Manufacturing US puts $125m into personalised RNA therapy production pharminent September 2, 2026